Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Accured Expenses (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Change in Accured Expenses for 6 consecutive years, with -$394856.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 72.58% year-over-year to -$394856.0, compared with a TTM value of $941524.0 through Dec 2025, up 176.48%, and an annual FY2025 reading of $941524.0, up 176.48% over the prior year.
  • Change in Accured Expenses was -$394856.0 for Q4 2025 at SAB Biotherapeutics, down from -$287490.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.0 million in Q1 2021 and bottomed at -$2.0 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is -$57878.8, with a median of -$303860.5 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses skyrocketed 22512.85% in 2021, then crashed 265.24% in 2023.
  • Year by year, Change in Accured Expenses stood at $276329.0 in 2021, then plummeted by 215.89% to -$320231.0 in 2022, then skyrocketed by 538.06% to $1.4 million in 2023, then crashed by 202.66% to -$1.4 million in 2024, then skyrocketed by 72.58% to -$394856.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for SABS at -$394856.0 in Q4 2025, -$287490.0 in Q3 2025, and $1.0 million in Q2 2025.